• Je něco špatně v tomto záznamu ?

Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera

P. Votavova, J. Tomala, M. Kovar,

. 2014 ; 159 (1-2) : 1-10.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc15008325

IL-2 and IL-15 are structurally relative cytokines that share two receptor subunits, CD132 (γ(c) chain) and CD122 (β chain). However, the expression pattern and physiological role of IL-2 and IL-15 private receptor α chains CD25 and IL-15Rα, respectively, are strikingly different. CD25, together with CD122 and CD132, forms a trimeric high affinity IL-2 receptor that is expressed and functions on cells acquiring an IL-2 signal. Conversely, IL-15Rα is expressed and binds IL-15 with high affinity per se already in the endoplasmic reticulum of the IL-15 producing cells and it presents IL-15 to cells expressing CD122/CD132 dimeric receptor in trans. Thus, while IL-2 is secreted almost exclusively by activated T cells and acts as a free molecule, IL-15 is expressed mostly by myeloid cells and works as a cell surface-associated cytokine. Interestingly, the in vivo biological activity of IL-2 can be dramatically increased through complexing with certain anti-IL-2 mAbs; such IL-2/anti-IL-2 mAbs immunocomplexes selectively stimulate the proliferation of a distinct population of immune cells, depending on the clone of the anti-IL-2 mAb used. IL-2/S4B6 mAb immunocomplexes are highly stimulatory for CD122(high) populations (memory CD8(+) T and NK cells) and intermediately also for CD25(high) populations (Treg and activated T cells), while IL-2/JES6-1 mAb immunocomplexes enormously expand only CD25(high) cells. Although IL-2 immunocomplexes are much more potent than IL-2 in vivo, they show comparable to slightly lower activity in vitro. The in vivo biological activity of IL-15 can be dramatically increased through complexing with recombinant IL-15Rα-Fc chimera; however, IL-15/IL-15Rα-Fc complexes are significantly more potent than IL-15 both in vivo and in vitro. In this review we summarize and discuss the features and biological relevance of IL-2/anti-IL-2 mAbs and IL-15/IL-15Rα-Fc complexes, and try to foreshadow their potential in immunological research and immunotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008325
003      
CZ-PrNML
005      
20150325110602.0
007      
ta
008      
150306s2014 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.imlet.2014.01.017 $2 doi
035    __
$a (PubMed)24512738
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Votavova, Petra $u Laboratory of Tumor Immunology, Institute of Microbiology of Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic.
245    10
$a Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera / $c P. Votavova, J. Tomala, M. Kovar,
520    9_
$a IL-2 and IL-15 are structurally relative cytokines that share two receptor subunits, CD132 (γ(c) chain) and CD122 (β chain). However, the expression pattern and physiological role of IL-2 and IL-15 private receptor α chains CD25 and IL-15Rα, respectively, are strikingly different. CD25, together with CD122 and CD132, forms a trimeric high affinity IL-2 receptor that is expressed and functions on cells acquiring an IL-2 signal. Conversely, IL-15Rα is expressed and binds IL-15 with high affinity per se already in the endoplasmic reticulum of the IL-15 producing cells and it presents IL-15 to cells expressing CD122/CD132 dimeric receptor in trans. Thus, while IL-2 is secreted almost exclusively by activated T cells and acts as a free molecule, IL-15 is expressed mostly by myeloid cells and works as a cell surface-associated cytokine. Interestingly, the in vivo biological activity of IL-2 can be dramatically increased through complexing with certain anti-IL-2 mAbs; such IL-2/anti-IL-2 mAbs immunocomplexes selectively stimulate the proliferation of a distinct population of immune cells, depending on the clone of the anti-IL-2 mAb used. IL-2/S4B6 mAb immunocomplexes are highly stimulatory for CD122(high) populations (memory CD8(+) T and NK cells) and intermediately also for CD25(high) populations (Treg and activated T cells), while IL-2/JES6-1 mAb immunocomplexes enormously expand only CD25(high) cells. Although IL-2 immunocomplexes are much more potent than IL-2 in vivo, they show comparable to slightly lower activity in vitro. The in vivo biological activity of IL-15 can be dramatically increased through complexing with recombinant IL-15Rα-Fc chimera; however, IL-15/IL-15Rα-Fc complexes are significantly more potent than IL-15 both in vivo and in vitro. In this review we summarize and discuss the features and biological relevance of IL-2/anti-IL-2 mAbs and IL-15/IL-15Rα-Fc complexes, and try to foreshadow their potential in immunological research and immunotherapy.
650    _2
$a zvířata $7 D000818
650    _2
$a monoklonální protilátky $x chemie $7 D000911
650    _2
$a imunokomplex $x genetika $x imunologie $x farmakologie $7 D000936
650    _2
$a CD8-pozitivní T-lymfocyty $x cytologie $x účinky léků $x imunologie $7 D018414
650    _2
$a regulace genové exprese $7 D005786
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobuliny - Fc fragmenty $x chemie $7 D007141
650    _2
$a receptory interleukinů - společná gama-podjednotka $x genetika $x imunologie $7 D053631
650    _2
$a interleukin-15 $x genetika $x imunologie $x farmakologie $7 D019409
650    _2
$a receptor interleukinu-15 - alfa-podjednotka $x genetika $x imunologie $7 D053720
650    _2
$a interleukin-2 $x genetika $x imunologie $x farmakologie $7 D007376
650    _2
$a receptor interleukinu-2 - alfa-podjednotka $x genetika $x imunologie $7 D053645
650    _2
$a buňky NK $x cytologie $x účinky léků $x imunologie $7 D007694
650    _2
$a myši $7 D051379
650    _2
$a signální transdukce $7 D015398
650    _2
$a regulační T-lymfocyty $x cytologie $x účinky léků $x imunologie $7 D050378
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Tomala, Jakub $u Laboratory of Tumor Immunology, Institute of Microbiology of Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic.
700    1_
$a Kovar, Marek $u Laboratory of Tumor Immunology, Institute of Microbiology of Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic. Electronic address: makovar@biomed.cas.cz.
773    0_
$w MED00002200 $t Immunology letters $x 1879-0542 $g Roč. 159, č. 1-2 (2014), s. 1-10
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24512738 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20150325110851 $b ABA008
999    __
$a ok $b bmc $g 1065598 $s 891125
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 159 $c 1-2 $d 1-10 $i 1879-0542 $m Immunology letters $n Immunol Lett $x MED00002200
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...